Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2006 May;21(3):177-9.
doi: 10.1097/01.yic.0000194378.65460.ef.

An open-label study of escitalopram in body dysmorphic disorder

Katharine A Phillips  1
Affiliations
Clinical Trial

An open-label study of escitalopram in body dysmorphic disorder

Katharine A Phillips. Int Clin Psychopharmacol. 2006 May.

Abstract

Body dysmorphic disorder (BDD) is a relatively common and impairing disorder. Selective serotonin reuptake inhibitors (SRIs) appear selectively efficacious for BDD, but pharmacotherapy research is limited, and escitalopram has not been studied. Fifteen subjects with BDD were treated with escitalopram and assessed with reliable and valid measures. BDD symptoms significantly improved (P<0.001), and 73.3% (n=11) of subjects were responders. Of the subjects, 46.7% were very much improved, and 33.3% were much improved. Depressive symptoms, delusionality, functioning and quality of life also significantly improved. Escitalopram was well tolerated. These preliminary data suggest that escitalopram is safe and efficacious for BDD.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Yale–Brown Obsessive Compulsive Scale modified for Body Dysmorphic Disorder (BDD-YBOCS) scores over time in 15 subjects with body dysmorphic disorder treated with escitalopram. There was a significant time effect [F(3.7, 52.3) = 15.9, P < 0.001]; all observations represent last observation carried forward.
See this image and copyright information in PMC

References

    1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edn. Washington, DC: American Psychiatric Association; 1994.
    1. Eisen JL, Phillips KA, Baer L, Beer DA, Atala KD, Rasmussen SA. The Brown Assessment of Beliefs Scale: reliability and validity. Am J Psychiatry. 1998;155:102–108. - PubMed
    1. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29:321–326. - PubMed
    1. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV-TR axis I disorders, research version, patient edn (SCID-I/P) New York, New York: Biometrics Research, New York State Psychiatric Institute; 2002.
    1. Hollander E, Allen A, Kwon J, Aronowitz B, Schmeidler J, Wong C, et al. Clomipramine versus desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch Gen Psychiatry. 1999;56:1033–1039. - PubMed

Publication types

MeSH terms

Substances